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Abstracts of Invited and Proffered Papers
The Fourth Gordon Hamilton-Fairley Memorial
Lecture, delivered by Dr S. Brenner, MRC
Laboratory of Molecular Biology, Cambridge, was
entitled Genes, Growth and Differentiation.
Endocrinology of prostatic cancer
K. Griffiths
Tenovus Institute for Cancer Research, Heath Park,
CardiffCF4 4XX
Despite intense investigation, the roles of the
various hormones that influence the prostate gland
in the aetiology of prostatic cancer remain to be
elucidated. Some evidence has emerged from the
work of the British Prostate Study Group to
suggest that hormone analysis will allow the identi-
fication of these patients presenting with prostatic
cancer who are at greater risk of rapid disease
progression and more effective and aggressive
treatment should probably be considered for these
patients. The monitoring of hormone changes in
the plasma of patients being treated is also seen to
be an advantage in determining the course of
therapy and a recent assessment of the use of the
new LH-RH analogue (ICI 118630) for prostatic
cancer therapy appears very encouraging. The value
of specific antisera to proteins, isolated for various
types of prostatic tissue, in drug-targetting studies,
is being assessed in a number of centres and may
again offer a new approach to treatment.
The action of oestrogens and antioestrogens on
cultured breast tumour cells
H. Rochefort, F. Capony, D. Chalbos, M. Garcia,
F. Veith, F. Vignon & B. Westley
Unite d'Endocrinologie Cellulaire et Moleculaire
(U 148), INSERM, 60 Rue de Navacelles, 3410
Montpellier, France.
Oestrogens and antioestrogens regulate the
production of specific proteins by, and the growth
of, breast cancer cells. The mechanisms involved
have been studied in culture using oestrogen
receptor (RE) positive cell lines derived from
metastatic breast cancers. In MCF7 cells oestradiol
increases progesterone receptor levels and the
production of a 52,000 dalton (52K) glycoprotein
which is released into the culture medium.
Oestrogens also transform the cell ultrastructure:
the number and length of microvillae and the
production of secretory granules are increased,
while attachment of cells to plastic is decreased.
Antioestrogens, Tamoxifen and Progestins, do not
themselves induce the 52K protein, but inhibit its
induction by oestrogens. Using specific antibodies,
the presence of this protein has been demonstrated
in several pleural metastases of breast cancer and in
primary breast cancer, but not in the normal
mammary cell line HBL100 or in adenofibroma.
Since it is secreted or shed into the culture medium,
the 52K protein is a potential circulating marker of
oestrogen dependency in breast cancer. Oestrogen
increases the growth of RE positive cells in vitro if
the culture medium is sufficiently depleted of
endogenous oestrogens and other mitogens. This
direct effect of oestrogens in cell culture does not
exclude the existence of additional indirect effects in
vivo, mediated by growth factors produced by other
tissues (oestromedins). However, it does allow the
mechanism by which oestrogens stimulate the
proliferation of RE positive cell lines to be studied
in vitro. Several indirect lines of evidence suggested
that oestrogens might stimulate the growth of
breast cancer cells by inducing them to produce
growth factors which would then stimulate their
proliferation (Autocrine mechanism). We have
found that non dialysable, protease sensitive,
oestrogen induced factors from conditioned media
*Enquiries to the BACR Secretariat, c/o Institute of
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promote the growth of E2 deprived MCF7 cells and
of RE negative cells. These factors are retained on
Con A sepharose. The recent preparation of mono-
clonal antibodies to the 52K protein or other
oestrogen regulated glycoproteins released by
MCF7 cells are responsible for this mitogenic
activity. Antioestrogens appear to decrease the
production of these factors in the medium; their
action being mediated either by the oestrogen
receptor (Tamoxifen) or by the progesterone
receptor (Progestins).
We conclude that oestrogen responsive human
mammary cell lines provide simple model systems
which can faithfully reproduce the in vivo effect of
oestrogens and antioestrogens in patients. They are
therefore useful for understanding the mechanisms
of hormone regulation of breast cancer and for
improving its medical management.
Molecular biology of calcitonin and katacalcin
I. Maclntyre
Endocrine Unit, Department of Chemical Pathology,
Royal Postgraduate Medical School, Ducane Road,
London, W12 OHS
Calcitonin is synthesized by the C-cells as a large
precursor (21 K). The hormone is flanked on both
sides by previously unrecognised peptides. The C-
terminal flanking peptide, katacalcin, is secreted
together with calcitonin. The plasma concentrations
of these two hormones are approximately
equimolar: as expected the plasma levels of
katacalcin vary with calcitonin.
Further, it has recently been shown in the rat
that a different peptide is also encoded by the
calcitonin gene. This 37 aminoacid peptide (CGRP)
is found in the nervous system, where it may act as
a neuro-modulator. Differential tissue-specific
mRNA processing is apparently the explanation for
the different tissue distribution reported in the rat
for calcitonin and CGRP. These findings may have
important physiological consequences but it
remains to be determined whether a similar peptide
is present in human tissues.
Alimentary tract tumours secreting regulatory
peptides
S.R. Bloom
Royal Postgraduate Medical School, Hammersmith
Hospital, Ducane Road, London WJ2 OHS
Use of gene transfer to analyse gene expression and
hormone control
M.G. Parker
Imperial Cancer Research Fund, P.O. Box 123,
Lincoln's Inn Fields, London WC2A 3PX
The ability to introduce DNA into eucaryotic cells
has provided a means for analysing the expression
of cloned genes. By manipulating the genes in vitro,
using recombinant DNA techniques, it is possible
to identify regulatory DNA sequences which are
important for individual steps in gene expression.
By means of this approach we are analysing the
mechanism whereby testosterone regulates the
expression of genes encoding prostatic steroid
binding protein. The genes have been introduced
into an androgen-responsive mouse cell line where
their expression is accurate and, in certain cases, is
stimulated up to 5-fold by testosterone. To
delineate the site of action of the hormone we have
constructed chimaeric genes consisting of putative
C3 gene promotors and regulatory DNA sequences
together with a marker gene. Expression of the
marker gene was stimulated by less than two-fold
by testosterone. These data suggest that in mouse
cells, testosterone does not appear to modulate C3
gene expression by stimulating gene transcription
and in certain clones may be acting post-
transcriptionally.
In contrast, glucocorticoids stimulate the
transcription of mouse mammary tumour virus by
interacting with DNA adjacent to the viral
promoter, even in heterologous cells. Similarly,
progesterone and dexamethasone interact with a
region of DNA in the egg white genes which is
adjacent to the promoter but, in these cases,
transcription was stimulated by steroid only in
oviduct cells. Therefore, it is likely that tissue
specific factors, in addition to steroid-receptor
complexes, are required for hormones to stimulate
the transcription of certain genes.
New approaches to breast cancer- The potential of
monoclonal antibodies
R.C. Coombes, R. Rainsbury, W.H. Redding &
A.M. Neville
The Ludwig Institute for Cancer Research (London
Branch), The Royal Marsden Hospital, Sutton,
Surrey, SM2 5PX
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applications to diagnosis and therapy of human
breast cancer.
We have investigated their use in (a) detecting
micrometastases and (b) radio-localisation. In terms
of the former application we are currently
substituting a monoclonal antibody against milk fat
globule membrane (LICR-LON-M8) for a
polyclonal antiserum and it appears to have an
equal ability to detect micrometastases in bone
marrow.
Currently using the polyclonal antiserum, we can
detect micrometastases in 28% of patients with
primary breast cancer. Using the same monoclonal
we have labelled it with '1tlndium-diethylene-
triaminepentaaceticacid complex and this has been
shown to localise in bone metastases in nearly all
patients with overt skeletal disease both by auto-
radiography and external scanning.
A final application that we have investigated is
the use of antibodies in killing breast cancer cells in
bone marrow. If we could achieve this we could
rescue patients with "cleaned-up" bone marrow
after high-dose therapy. We have evaluated one
such monoclonal (LICR-LON-Fib75) which is
cytotoxic for breast cancer cells with rabbit
complement. Since its effects in the colony-forming-
capacity of the bone marrow are variable we are
also exploring the use of toxin-linked LICR-LON-
Fib75.
None of these monoclonals are breast cancer-
specific and a major component of the work of this
group is in trying to raise a breast-specific
monoclonal reagent.
The endorphins
L.H. Rees
Department of Chemical Endocrinology,
Bartholomew's Hospital, London, ECIA 7BE
St
Endorphins is a generic name encompassing several
families of endogeneous opioid peptides, all with
differing affinities for different classes of opiate
receptors. Despite technical difficulties surrounding
their measurement, a mass of data has accumulated
implicating them in the pathogenesis of diverse
conditions such as exercise-induced amenorrhoea,
septic shock, chlorpropamide-alcohol flushing and
alcoholism in humans as well as neurooncogenic
events in experimental animals. Their secretion by
phaeochromocytomas and ectopic ACTH-secreting
tumours raised questions concerning their role in
non-metastatic manifestations of malignant disease.
Furthermore, fascinating data now exist implicating
their differential release following electro-
B.J.C.-F
acupuncture (EAP) given for pain relief of heroin
withdrawal symptoms suggesting that the electrical
frequency of the EAP determines which opioid
peptide is released. Naloxone, the opioid antagonist
which preferentially blocks u receptors has been
extensively used in studies of the role of
endogenous opioids but until good A and 6 receptor
antagonists become available the consequences of
their effective antagonism will not be known. In
future availability of more specific agonists and
antagonists will allow manipulation of different
receptor populations. Furthermore, the search for
enkephalin analogues with therapeutic efficacy but
without addictive properties continues unbated.
These areas and many others will require further
exploration before the complexity of interactions of
endogenous opioids is understood. We must
conclude that we are still on the threshold of
understanding their physiological roles and
involvement in disease states.
Abstracts of members' proffered papers
Flow cytometric and physical
glucocorticoid-induced cell death
studies of
N.O. MacKinnon', D.M. Lamb', J.E.D. Dyson', P.
Quirke2 & C.C. Bird2
'Department of Radiotherapy, Tunbridge Building,
Cookridge Hospital, 2Department of Pathology,
Leeds LS16 6QB
The phenomenon of "programmed" cell death or
apoptosis (shrinkage necrosis) has been suggested as
an important factor in explaining the observed slow
growth rates of tumours as compared to rates
calculated on content of cycling cells (Wyllie et al.,
1980, Int. Rev. Cytol., 68, 251). Certain human
lymphoid cell lines are thus in use as possible
models for the study of apoptosis in vitro.
Preliminary studies employing physical techniques
with the CCRF-CEM and CCRF-CEM-C7 cell
lines have shown changes ocurring during methyl-
prednisolone-induced cell death which are
consistent with observed changes in morphology
during apoptosis in vitro and in vivo. Increasing
condensation of cellular cytoplasm and
decondensation of nuclear chromatin (assessed
using fluorescence polarization and time dependent
changes in staining of cellular DNA respectively)
have been observed as cell death progresses.
Concurrent flow cytometric studies have shown that
following these changes the cells become382 ABSTRACTS OF INVITED AND PROFFERED PAPERS
permeable to vital dyes and then form a well defined
subpopulation on the green vs red fluorescence
scattergram. A similarly defined subpopulation is
also observed when cell suspensions from whole
tumours are analysed. This suggests that the latter
are also apoptotic cells, which would thus allow
the content of such cells in a given tumour biopsy
to be estimated. Purified fractions of these
subpopulations obtained by flow cytometric cell
sorting are being examined by electron microscopy
in order that their morphology may be compared.
Tritiated thymidine labelling index in human
prostatic cancer
C.E. Bumford, M.E. Lambert & N.J. Blacklock
Department of Urology, University Hospital ofSouth
Manchester, Nell Lane, Manchester M20 8LR
Tritiated Thymidine Labelling Index (LI) is a crude
but simple in vitro index of the proliferative activity
within a tumour and thus has potential as a
prognostic indicator. LIs have been determined by
the method of Meyer & Bauer (1975)* on 22
specimens of human prostatic carcinoma (median
LI 0.28%, range 0.0-2.77%), 37 specimens of
human benign prostatic hyperplasia (median LI
0.12, range 0.0-0.65%) and 6 specimens of normal
human prostate (median LI 0.04, range 0.0-0.23%).
Prostatic carcinomas of patients presenting with
metastases had a significantly higher LI than those
of patients without detectable metastases (P=0.04
by the Kruskal-Wallis non-parametric ANOVAR);
these former patients have an appreciably worse
prognosis.
Although the follow-up on these patients (mean
16 months) is not adequate to assess the
independent prognostic value of LI, those patients
with the highest LIs in this series have rapidly
advancing disease.
Non-protein-bound estradiol, SHBG, breast cancer
and breast cancer risk
P.F. Bruning, J.M.G. Bonfrer, D. Linders, J. van
Loon & A.A.M. Hart
The Netherlands Cancer Institute, Plesmanlaan 121,
1066 CX Amsterdam, The Netherlands
*Meyer and Bauer (1975) etc.
It has been shown that, despite apparently normal
plasma concentration of estradiol (E2), the
percentage of non-protein-bound E2, which is
supposed to be biologically active, is abnormally
high in breast cancer patients. We have developed a
similar assay of non-protein-bound E2. Heparinized
plasma was obtained from (a) 26 women at risk for
breast cancer (mother and at least one sister having
breast cancer); (b) 11 normal women matched for
age, parity, Quetelet index and socioeconomic
factors; (c) 10 women with histologically proven
benign breast disease; (d) 17 women curatively
treated for T1NoMo breast cancer at least 6 months
ago. All women were premenopausal. We have
collected pooled plasma in the luteal phase. The
mean values + s.d. of non-bound E2 were (a)
1.78+0.28; (b) 1.70+0.54; (c) 1.84+0.34 and (d)
1.86+0.40% of the total E2 concentrations.
Differences were statistically not significant. An
inverse correlation between SHBG and non-bound
E2 was found (P<0.0001). Analysis of co-variance
demonstrated that the regression lines for log
SHBG vs. log non-bound E2 were identical for the
4 groups. In 40 serum bank samples from pre- and
post-menopausal patients having breast cancer the
mean non-bound E2 was 1.59+0.41% of the total
E2. Log SHBG and log non-bound E2 showed
again very good correlation; the regression line ran
parallel with those of groups A-D though
significantly lower. Our preliminary results confirm
a very strong inverse correlation between non-
bound E2 and SHBG. There is no difference in
non-bound E2 between premenopausal women at
risk for breast cancer, normal matched controls,
women with benign breast disease and patients
cured for early breast cancer or having breast
cancer.
Peroxidase activity, a possible prognostic marker in
breast carcinoma
M.J. Duffy, M. O'Connell, G.J. Duffy, B. Cantwell,
J. Fennelly, L. O'Siorain & R. Conroy
Depts. of Nuclear Medicine & Oncology, St
Vincent's Hosp. Dublin 4
Peroxidase activity is massively induced in the
immature rat uterus following estradiol
administration. If a similar induction occurred in
breast carcinomas peroxidase could be a marker for
a functional estradiol receptor (ER) and thus be of
great value in predicting hormone-dependent
tumours. Although peroxidase activity has been
reported to be higher in some hormone-dependent
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independent tumours, no correlation has been
found between ER and peroxidase activity in
human breast carcinomas. Thus peroxidase is
unlikely to be a marker for predicting hormone-
dependent human breast tumours.
On the other hand peroxidase activity may be a
prognostic marker in breast cancer. In this
investigation, patients whose tumours possessed
peroxidase activity had both shorter disease free
interval and shorter survival than patients with
peroxidase-negative tumours. These differences were
statistically significant; for disease free interval
P=0.0474; for survival P=0.0165. Patients with
ER-positive tumours also had a longer disease-free
interval and longer survival than ER-negative
tumours. However since ER were mostly confined
to low grade and low stage tumours, this protein
may not be a totally independent prognostic
marker. In contrast, peroxidase activity showed no
relationship to tumour stage or grade. It may
however be a measure of lymphocyte infiltration of
the tumour. (Duffy et al., 1982 Eur. J. Cancer, 18,
453). Conclusion: Although peroxidase activity is
unlikely to be a marker for hormone-dependent
breast tumours, its presence in these tumours is a
bad prognostic feature and its absence suggests a
good prognosis.
Increased activity of dihydropteridine reductase in
human breast tumours
J.A. Blair, P.A. Barford, C. Eggar & G.D. Oates
Department of Chemistry, University of Aston,
Birmingham, B4 7ET and The General Hospital,
Birmingham, B4 6NH
The enzyme dihydropteridine reductase (DHPR) is
widely distributed in mammalian tissues. Its known
functions are the reduction of quinonoid
dihydrobiopterin to tetrahydrobiopterin and
quinonoid dihydrofolate to tetrahydrofolate.
Measurement of DHPR activity in human breast
tumours and matched adjacent apparently non-
malignant tissue obtained at operation shows that
DHPR activity is very significantly higher in the
tumour than in the control tissue. Similar
measurements with human gut cancers show no
difference between tumour and control tissue.
In the rat large doses of oestrogens increase
tissue DHPR activity. In man measure erythrocyte
DHPR activity increases with increased exposure to
oestrogens. It has been previously reported that in
human breast tumours DHPR activity correlates
well with oestrogen receptor density.
It therefore appears likely that the increased
DHPR activity in human breast tumours is due to
the increased uptake by the tumour tissue of
oestrogen. Measurement of DHPR activity in
breast tumours and its comparison with normal
adjacent tissue may be a valuable procedure in the
prognosis and treatment of breast cancer.
Studies on the differentiation of human astroglioma
cells
M. Weir, A. Hunt, A.J. Patel & D.G.T. Thomas
Department of Neurological Surgery and MRC
Developmental Neurobiology Unit, Institute of
Neurology, Queen Square, London WCJN 3BG
The life expectancy of a patient with a low grade
astrocytoma is much greater than one with a high-
grade tumour. Since low grade astrocytoma contain
relatively more differentiated cells, the
understanding of differentiation in astroglial cells
would be clinically useful. Recently, we have shown
that the developmental increases in the astrocyte
enriched proteins, glutamine synthetase (GS) and
glial fibrillary acidic (GFA) protein are related to
maturation rather than proliferation of astrocytes.
These proteins were used to study the effect of
various metabolic factors on the differentiation of
glioma and normal astrocyte cells in culture. In
human glioma cell line U251MG ethanol treatment
was found to decrease GS and increase GFA
protein concentrations in a dose dependent manner
(IC50, 0.05-0.1%). In contrast, alcohol had no
effect on either the morphology (at the light
microscope level), or cell numbers, or total protein
content of these cells. The effect of alcohol could be
prevented by concomitant addition of
dexamethasone (DEX). Similar effects of alcohol
was observed in 10 primary cultures derived from
various grades of astrocytoma. The effect on
astrocyte-enriched proteins may be specific to
transformed cells as alcohol (up to 1%) has little
appreciable effect on normal mammalian astrocytes.
Other factors studied were addition of DEX and
removal of glutamine from culture medium; both
resulted in a major increase of GS protein, though
tumours varied in their sensitivity. These effects do
not seem to be specific to the transformed cells,
since both the removal of glutamine and addition
of DEX resulted in a marked increase in GS in
normal astrocyte cultures. Furthermore both these
effects were additive in all types of astroglial cells.
These results suggest involvement of more than one
mechanism in the regulation of astrocyte enriched
proteins in both astroglioma and normal
astrologlial cells.384 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Suppression of growth of a human tumour xenograft
by a vindesine monoclonal antibody conjugate
M.V. Pimm', G.F. Rowland2, R.G. Simmonds2, H.
Marsden2, M.J. Embleton', E. Jacobs' & R.W.
Baldwin'
'Cancer Research Campaign Laboratories,
University of Nottingham, 2Lilly Research Centre
Ltd., Windlesham, Surrey
The production of anti-tumour monoclonal
antibodies has prompted the development of
conjugates with anti-tumour agents for specific
targeting to tumour sites. Monoclonal antibody
791T/36 (mouse IgG2b), against the human
osteogenic sarcoma cell line 791T, was radiolabelled
with 125I, and localized in xenografts of 791T in
immunodeprived mice. Kinetic studies showed that
the maximum degree of localization was achieved 3
to 4 days after antibody administration. The
maximum tumour level of antibody achieved was
80ygg-' of tissue following injection of 100-
200mgkgI body weight of 791T/36 antibody.
The vinca alkaloid Vindesine (VDS) was
conjugated covalently to 791T/36 antibody (3:1 to
6:1 molar ratios). These conjugates were cytotoxic
in vitro specifically for target cells expressing the
791T/36 defined antigen and 1251 labelled
conjugates localized in vivo in 791T xenografts. The
therapeutic effects of conjugate was tested against
791T xenografts. Mice were injected at 3 to 4 day
intervals with up to 180mgkg-' 791T/36-
5mgkg-' VDS/injection (total doses up to
1.6gkg-' 791T/36-45mgkg-' VDS) and this
significantly retarded tumour growth with no
toxicity to the mice. Free antibody had no influence
on tumour growth. Free VDS was significantly
tumour suppressive at doses equivalent to those in
the conjugate, but was also markedly toxic to the
mice since the doses used exceeded the established
acute LD50 of the drug (6.3mgkg-1, Todd et al.,
1976 J. Toxicol. Environ. Health, 1, 843).
These studies suggest that drug-antibody
conjugates could have considerable potential for
selective anti-tumour therapy.
Human tumour cells "escaping" a cytotoxic
monoclonal antibody-methotrexate conjugate do not
constitute permanently resistant clones
M.J. Embleton, E. Jacobs, M.C. Garnett & R.W.
Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD
In evaluating monoclonal antibody-drug conjugates
as anti-tumour agents, one potential problem is the
emergence of resistant tumour cell clones. In
addition to selection for drug-resistance it is
possible that clones of diminished antigenicity could
arise as a result of modulation or selection. We
have measured both parameters in "resistant"
clones of a human osteogenic sarcoma line (791T)
isolated after treatment with a monoclonal
antibody-methotrexate (MoAb-MTX) conjugate.
Parental cells exposed at low density in vitro to
MoAb-MTX containing the equivalent of 50 or
lOOngml-' methotrexate (MTX) showed plating
efficiencies of 0.28% and 0.08% of control levels,
respectively. Of 15 colonies isolated at these doses
and subsequently propagated, 11 failed to undergo
more than a few cell divisions and only 4 developed
into cloned lines. The "resistant" clones were
assayed for antigenicity by flow cytometry using
fluorescein isothiocyanate-conjugated monoclonal
antibody, and for drug-resistance by assessing their
plating efficiency in free MTX. Two clones showed
antibody binding within the normal range for the
parental 791T line, and two were more antigenic.
Three of the clones were as susceptible to MTX
toxicity as 791T cells (IC50 8 to l0ngml-') and the
fourth was only slightly less sensitive (IC,0
17ngml-'). These findings suggested that the
clones would not resist a further exposure to the
MoAb-MTX conjugate, and this was confirmed by
showing that the IC50 of conjugate for both
parental cells and clones was in the range 1.5 to
3 ngml- I (in terms of MTX).
It is concluded that cells emerging after exposure
to a cytotoxic conjugate are not necessarily
resistant, but may either be incapable of unlimited
growth or sensitive to further attack by the same
conjugate.
Comparison of in vitro chemosensitivities of
continuous cell lines derived from transitional cell
cancers of the human bladder
P.J. Hepburn & J.R.W. Masters
Dept. Histopathology, Institute of Urology, St Paul's
Hospital, London WC2H 9AE
The aim of this study was to measure the in vitro
sensitivities to chemotherapeutic drugs of
continuous cell lines derived from human tumours
of one histological type. Eight lines derived from
transitional cell cancers of the human bladder,
MGH-U1, MGH-U2, T24, RT112, TCCSUP, 253J,
HT1376 and RT4, were exposed to a cell cycle
phase-specific drug, methotrexate and a cell cycleABSTRACTS OF INVITED AND PROFFERED PAPERS 385
specific drug, adriamycin. The in vitro sensitivities
following exposure for 24h to a range of drug
concentrations were measured using a clonogenic
assay on plastic. We have shown that three of these
lines, MGH-Ul, MGH-U2 and T24 are cross-
contaminated (O'Toole et al., 1983, Nature, 301,
429). The in vitro sensitivities of these three lines
were similar, but the remaining five lines showed a
wide range of response. The proportion of
clonogenic cells surviving exposure to lOOngml-1
methotrexate ranged from 1.5% for MGH-Ul to
89.5% for HT1376, and to 30ngml-1 adriamycin
from 0.7% for MGH-Ul to 42% for HT1376. The
sensitivities of the cell lines showed the same rank
order for each drug. Cytotoxicity was also related
to growth rate, in that the higher the population
doubling time and colony forming efficiency the
more sensitive were the cells to each drug. In
conclusion it has been shown that continuous cell
lines derived from one histological type of tumour
show a wide range of drug sensitivities. Therefore,
data derived from one cell line may not accurately
reflect the drug sensitivities of tumours of that
histological type.
Are the drugs that have been stored in solution still
active when added to an in vitro chemosensitivity
assay? A review with special reference to nitrosoureas
and nitrogen mustards
A.G. Bosanquet
Department of Clinical Investigation, Royal United
Hospital, Combe Park, Bath BAI 3NG
Many drugs are required in solution at short notice
for an in vitro chemosensitivity assay. They are
often made up in phosphate buffered saline (PBS)
or saline and stored frozen until required. However,
(a) it has been suggested that solutions of BCNU
are unstable under these conditions, (b) some drugs
have very short half lives in solution, and (c) I have
found that aqueous solutions of 2,5-diaziridinyl-3,6-
bis(2-hydroxyethyl-amino)-1,4-benzoquinone (BZQ)
irreversably precipitate on being frozen. These
instances suggest that care ought to be taken in the
preparation and storage of drug solutions for in
vitro use. Some drugs are very stable in solution
(prednisolone, cytosine arabinoside) so that they
can be stored at 4°C for some months with no
detrimental effects; solutions of others need to be
stored frozen, but 1-2h at room temperature will
not affect them significantly (vincristine,
vinblastine, vindesine bleomycin, adriamycin,
actinomycin D, methotrexate) whilst the nitrogen
mustards and nitrosoureas must be treated with
care. It is suggested that nitrosoureas be stored in
ethanol solution at -40°C or lower and diluted in
saline pH 5 on the day of the assay to be most
stable; BCNU is slightly less stable than CCNU
and MeCCNU. Nitrogen mustards can be frozen in
solution, but not left at room temperature for any
length of time. The values of to.95 (5% degraded) in
PBS (pH 7) at 25°C for chlorambucil, melphalan,
nitrogen mustard and 4-hydroperoxycyclophos-
phamide are about 15, 45, 45 and 1 h
respectively.
A mechanism for folate catabolism
J.A. Blair, P.A. Barford, A. Sahota, C. Morar, M.
Surdhar & D. Al-Haddad
Department of Chemistry, University of Aston,
Birmingham B4 7ET
It is now well established that folate catabolism
occurs in man, rat, guinea pig and hamster giving
p-acetamidobenzoate and p-acetamidobenzoyl-
L-glutamate as metabolites derived from the
aminobenzoyl-L-glutamate moiety and urea, CO2
and unidentified fragments from the pterin portion.
In man and the rat this catabolism is decreased in
the presence of a tumour and in the rat is increased
by the administration of methotrexate, an inhibitor
of the reductases which maintain the tetrahydro-
folate pool. It is therefore important to establish
the mechanism of this catabolism.
Tetrahydrofolate is oxidised by dioxygen in
aqueous solution at neutral pH giving pterin and
p-aminobenzoyl-L-glutamate as scission products
by a free radical chain mechanism with superoxide
anion as chain carrier.
Tetrahydrofolate and tetrahydrobiopterin (a
model for tetrahydrofolate) are oxidised at an
increased rate in the presence of xanthine plus
xanthine oxidase and this oxidation is significantly
reduced by superoxide dismutase. Thus tetrahydro-
folate can be oxidised to scission products by
superoxide anion formed from an enzyme reaction.
In the hamster folate catabolism is significantly
increased after administration of large amounts of
allopurinol, xanthopterin and dihydroorotate,
compounds whose in vivo metabolism may increase
in vivo superoxide anion formation. Similar results
are obtained in the rat after doses of allopurinol.
Folate catabolism is therefore due to oxidation of
tetrahydrofolate by superoxide anion formed by
enzymic, phagocytic and chemical oxidation.386 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Plasma and tumour pharmacokinetics of benznidazole
in man
J.T. Roberts, N.M. Bleehen, P. Workman & M.I.
Walton
University Dept. and MRC Unit of Clinical
Oncology and Radiotherapeutics, Addenbrooke's
Hospital, Hills Road, Cambridge CB2 2QQ
Benznidazole has been reported to enhance the
response of mouse tumours to CCNU at plasma
and tumour concentrations which should be readily
attainable in man (Twentyman & Workman, (1983)
Br. J. Cancer, 48, 17). This enhancement is
considered greater than that seen in normal tissues,
resulting in a net therapeutic gain. As part of a
phase I assessment of this combination we have
determined the plasma, urine and tumour
pharmacokinetics of benznidazole by reverse phase
HPLC. Twenty-six patients have received benzni-
dazole in combination with CCNU, the benzni-
dazole dose being increased in successive groups of
patients from 4mgkg-' to 30mgkg-1. Both drugs
were given orally, benznidazole preceding CCNU
by 3 h. No evidence of saturation kinetics has been
seen at doses currently used. The mean plasma half
life (ti) was 12.8+0.5h (s.e., n=25). Plasma peak
concentration and AUC were linearly related to
dose over the whole range. As an example the
average peak plasma concentration at 8mgkg-
was 13.6+1 mgkl- 1 (n =7). The median peak time
was 4h. Approx. 60% of the drug was protein
bound. Approx. 6% of the dose was excreted
unchanged in the urine, the rest being unaccounted
for. Benznidazole concentrations have been
measured, at varying times, after oral admini-
stration of the drug, in biopsies from 11 patienrs
with brain tumours and 6 patients with tumours in
other sites. A plateau of maximum concentration is
seen over 2-6h with mean tumour plasma ratios of
88% for gliomas and 72% for non-brain tumours.
Absolute tumour concentrations of 8-9mgml - I
were readily achieved with doses of 8mgkg-1. We
have shown that it is possible to achieve in man
plasma and tumour levels of benznidazole which, in
the mouse model, produce effective enhancement of
CCNU response.
An assessment of staging procedures in patients with
small cell carcinoma of the bronchus (SCCB)
S.P. Lockhart, M.A. Cornbleet, M.V. Merrick',
S.G. Allan, R.C.F. Leonard & J.F. Smyth
Dept. of Clinical Oncology, 'Dept. of Nuclear
Medicine, Western General Hospital, Edinburgh EH4
2XU
Seventy patients with histologically proven SCCB
were investigated to determine the value of limited
staging (LS), clinical with haematological and
biochemical evaluation against full staging by
including bone scanning (BS), liver ultrasound
(LUS) and bone marrow (BM) examination. BS
was performed on 56 patients and positive in 16,
being the only positive procedure in 9 of those
patients fully staged. Alkaline phosphatase (AP)
and plasma calcium were not useful indicators of
bone disease. The result of BS could not be
predicted reliably from limited staging. LUS was
performed on 65 patients, positive in 12, being the
only positive staging test in just one patient. AP
and AST were not useful in predicting LUS results
but a normal LDH was highly correlated with
normal LUS. BM was performed on 47 patients
and abnormal in 4. This was not predicted by
blood count but was associated with elevated LDH.
Overall, 44 patients had all staging procedures.
Compared with LS, 15 were downstaged and 5
upstaged as a result of further procedures. After
full staging, 16 had extensive and 28 limited disease.
Elevated LDH was present in 9/16 patients with
metastatic disease but was also present in 8/28
patients with limited disease. Normal LDH
correctly predicted a normal LUS; unexpectedly,
elevated LDH was associated with abnormal BM.
Routine use of all investigations is expensive, time-
consuming and unnecessary for all patients. This
study indicates that using limited staging plus BS,
with BM and LUS only for those patients with
elevated LDH, only 2/44 patients would have been
incorrectly staged.
Methods of evaluating quality of life in cancer
patients
P. Selby', J.-A. Chapman' & N.F. Boyd2
'Department of Medicine, Institute of Cancer
Research, The Royal Marsden Hospital, Sutton,
Surrey, 2The Princess Margaret Hospital, Toronto,
Canada
Although the need to directly measure quality of
survival in the investigation of cancer treatment is
widely recognised, satisfactory methods have not
been established and their evaluation remains
complex and indirect. We have studied the use of a
self assessment measurement method in breast
cancer patients. Sixteen items describing general
health features were drawn from the SicknessABSTRACTS OF INVITED AND PROFFERED PAPERS 387
Impact Profile, a lengthy established method for
measuring functional status, 15 items describing
features of breast cancer were drawn from patients
opinions and clinical experience. Each item was
assessed by a linear analogue scale. The method
was shown to be reliable with test-retest
correlations of >0.7 for 23 items (Selby et al.,
1982, Proc. ASCO, p. 45) and internally consistant.
Validity of items cannot be established directly
since no standards exist. Estimates of validity were
made indirectly by comparisons with other
methods, by comparisons between items using
factor analysis and by comparisons with physician
scores in a total of 177 breast cancer patients.
Patients scores were generally highly correlated to
physician assessments with coefficients >0.6 in
25/31 items although the variance of patients scores
was greater than that of physicians. Scores were
highly correlated to scores in equivalent categories
of the Sickness Impact Profile with 6/7 coefficients
>0.6 for items which were directly comparable.
The factorial composition of the items' scores
revealed 5 closely inter-correlated groups of items
compatible with clinical experience.
The assessment of quality of life in cancer patients; a
fresh approach
S. Bindemann, R.A.V. Milsted, S.B. Kaye & K.C.
Calman
Department of Clinical Oncology, University of
Glasgow, Glasgow 12
Quality of life is highly relevant to management of
the Ca patient. However, difficulties in its
assessment are well known. This Department has
attempted an improved method by means of a self-
report questionnaire. A sample of Ca patients
(nlOO) and of control subjects (n80) were asked to
describe "the kind of person I am" by selecting
items from a "pool" of bi-polar items, e.g. "happy-
sad" etc. Subjects were then required to describe
perception of their ideal self, i.e. "the kind of
person I should like to be". Factor analysis
provided a statistical method for data reduction
into clusters of homogeneous items or factors. A
two-factor solution was adopted, viz. a factor of
"intrapsychic functioning" and a factor of
"anticipation of the future". Taking the first factor
only, as an example it is apparent that at its pole of
"unsatisfactory functioning", items such as "often
depressed", "seldom relaxed" etc. were the items
chosen. Conversely, the "satisfactory functioning"
pole was characterised by their polar alternatives,
i.e. "seldom depressed" etc. Computation of factor-
scores facilitated group values which indicate
position on a linear scale, having a zero mean with
unit s.d.'s + on either side. Results indicate
statistically significant discrepancies between Ca
patients and control Ss (subdivided into non-Ca
patients (n30) and non-patient Ss (n50)) in
"intrapsychic functioning" scores (analysis of
variance=P<0.05). Differences between these
discreet groups (using students' t) were as follows:
Ca patients and non-Ca patients P= <0.01; Ca
patients and non-patient Ss P= <0.01. Statistically
significant differences also differentiated Ca patients
from control Ss in the size of discrepancy between
actual and ideal self-perceptions (invariably greater
in the case of Ca patients). We hypothesise that
refinement of the measurement of such self-
perceptions by means of a self-evaluation question-
naire will greatly enhance assessment of quality of
life.
The effect of dose on the absorption of oral etoposide
V.J. Harvey, M.L. Slevin, S.P. Joel, A. Johnston &
P.F.M. Wrigley
Imperial Cancer Research Fund Department of
Medical Oncology, St Bartholomews and Hackney
Hospitals and Department of Clinical Pharmacology,
St Bartholomews Hospital, London ECIA 7BE
Etoposide is a semi-synthetic podophyllotoxin
derivative active in a variety of malignancies. It is
frequently administered orally but bioavailability
via this route is variable. The effect of dose on the
absorption of etoposide is unknown and has
therefore been studied in six patients with lung
carcinoma, acting as their own controls. All were
ambulant with normal hepatic and renal function.
Patients were fasted for 12h prior to treatment with
doses of 200, 400, and 600mg using oral capsules
on 3 consecutive days. The order of treatment was
randomised. The Area Under the Curve (AUC) was
proportionally greatest at 200mg. Doubling the
dose from 200mg to 400mg increased AUC by
only 44.2% and a further increase of 13.5%
occurred at a dose of 600mg. These data indicating
non-linear absorption of etoposide within the range
in clinical use may explain variations in the results
of reported studies. They may have important
implications for those chemotherapy regimens using
oral etoposide.
Etoposide containing combination chemotherapy for
Hodgkin's disease
P. Selby, B. Robinson & T.J. McElwain388 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Department of Medicine, Institute of Cancer
Research and The Royal Marsden Hospital, Downs
Road, Sutton, Surrey
Etoposide has been shown to be active in
Hodgkin's disease (Taylor et al., 1982, Cancer
Chemo. Pharmacol., 7, 175). We have explored the
combination of vincristine (Oncovin) 1.4mgm2 i.v.
days 1 and 8, prednisolone 40mg orally daily for 14
days, etoposide 200mgm-2 orally daily for 5 days
and chlorambucil 6mgm-2 orally daily for 14 days
(OPEC) in an attempt to increase the efficacy and
decrease the toxicity of treatment.
Thirty-nine patients (20 clinical stage (CS) IV, 9
CS III, and 10 CS II with poor prognostic features)
were treated. Thirty patients including 28 previously
untreated, 1 previously treated with radiotherapy
(RT) and 1 with chemotherapy (CT) 9 years earlier,
received OPEC alternating with Ch1VPP, an
established quadruple CT regimen. Ten CS II
patients also received RT. 23/70 (77%) entered
complete remission (CR). Nine patients who had
received previous chemotherapy were treated with
OPEC alone and 8 entered CR. Updated results of
remission duration will be presented. Nineteen of 39
patients reported nausea, 11/39 vomiting and 39/39
alopecia. Myelosuppression was mild, delaying
treatment in only 7 patients. Etoposide can be given
in full dosage in combination and the initial results
indicate acceptable efficacy.
An alternative regimen with adriamycin,
vincristine, prednisolone, etoposide and bleomycin
(HOPE-BLEO) has been piloted in 8 relapsed and
resistant patients. A safe schedule has been
established and initial results support its further
investigation.
Management of Hodgkin's disease in children, with
ChlVPP and involved field radiotherapy
B. Robinson, J. Kingston, T.J. McElwain, J.S.
Malpas & A. Barrett
Dept. Medical Oncology, St Bartholomews Hospital,
London, Royal Marsden Hospital, Sutton, Surrey
Eighty-two children, with Hodgkin's disease and no
previous treatment were treated at the Royal
Marsden (43) and Saint Bartholomew's (39)
Hospitals from 1974 to 1982. All had histology
review, full clinical staging, and 20 were patholo-
gically staged. Treatment involved field radio-
therapy, preceded by Ch1VPP in some, for Stage
IA and Stage IIA with favourable histology and
small bulk. Stage IIA with more than 3 sites
involved or bulk disease, and Stage III were treated
with Ch1VPP (6 courses) and radiotherapy of bulk
disease, and Stage IV with 10 courses ChlVPP.
Ch1VPP is chlorambucil, 6mgm-2, 0, daily,
procarbazine, 100mgm-2, 0, daily and predni-
solone, 25mgm2, 0, daily, for 14 days; vinblastine,
6mgm2, i.v. days 1 & 8.
The 58 males and 24 females (ratio 2.4:1) had a
mean age of 10.6 years, range 2.7-15.9 years.
Lymphadenopathy was a presenting feature in 90%,
B symptoms in 22%. Nodular sclerosis
predominated in both sexes, 60% overall in contra-
distinction to our previous experience. Stage distri-
bution was: 1,15; II,30; 111,24; IV,13. Complete
remission was documented in 79 or 96%, PR in 2,
PD in 1. At 5 years, survival was 93% and relapse-
free survival 84%, median follow up >4.5 years.
ChlVPP was non-toxic. Four died of HD, 1 of
pneumocystis carinii, 1 of pneumococcal
septicaemia 5 months after splenectomy. New
protocols aim to minimise late effects on fertility,
bone growth, induction of neoplasia and avoid
splenectomy which was associated with a 2-fold
greater infection risk.
Effects of cytotoxic therapy on proximal jejunal
absorptive function in man
D. Cunningham, L.M. Nelson, R.J. Morgan, P.R.
Mills, M. Soukop, C.S. McArdle & R.I. Russell
Gastroenterology Unit, Department of Medical
Oncology and Surgery, Glasgow Royal Infirmary
Cytotoxic therapy induces morphological changes
in the proximal intestine, being maximal between 24
and 48h after intravenous administration.
However, there is little published information on
the associated changes in function.
We have studied 6 patients receiving adjuvant
chemotherapy for adenocarcinoma of breast. Using
a triple lumen tube perfusion system, the
absorption of water and electrolytes before, and
45-48h after, administration of the i.v. cytotoxic
agents cyclophosphamide (300mgm 2),
methotrexate (40mgm-2) and 5-fluorouracil
(600mgm-2) were measured. Median (range) water
absorption dropped from 126 (40-142) to 72 (46-
142)ml per h per 30cm, but this was not
statistically significant with similar results for
electrolytes (Table I).ABSTRACTS OF INVITED AND PROFFERED PAPERS 389
Table I Absorption of water and electrolytes before and
after chemotherapy
Water Sodium Chloride
Pat. ml.h-1 30cm-1mmol.h-1 30cm-1mmol.h- 1 30cm-
No. Before After Before After Before After
1 103 142 10.7 12 9 12
2 123 84 10 9 9 8
3 142 84 14 6 11 6
4 137 46 10 6 12 3
5 40 55 3 5 3 5
6 129 98 14 10 13 9
In this study no consistent change in absorptive
function of the proximal jejunum following chemotherapy
was demonstrated.
The viability of marrow kept at 4°C
J.L. Millar, G. Joshi, R.D. Clutterbuck & I.E.
Smith
Institute of Cancer Research and Royal Marsden
Hospital, Sutton, Surrey
Very often, in autologous bone marrow
transplantation, the marrow cannot be returned to
the patient for some time after aspiration. This is
generally because the drug(s) given to the patient
have a finite clearance time and the marrow cannot
be reinfused until the drug(s) have reached a non
toxic level. During this time the marrow could be
cryopreserved but this results in loss of stem cells, is
costly and time consuming. The alternative is to
refrigerate the marrow until it can be returned but
clearly there is a limit to how long it will remain
viable. In both human and mouse marrow it is
possible to measure progenitor cells committed to
the granulocyte/macrophage pathway (GM-CFC)
but this in itself is no sure test of marrow viability.
We performed parallel studies between refrigerated
human marrow and mouse marrow in their
capacity to produce GM-CFC with time at 4°C. In
addition we used the mouse marrow to repopulate
lethally irradiated mice. The mouse marrow
inoculum was chosen to be just sufficient to keep
the mice alive at the beginning of the experiment so
that any decline in repopulating ability was
reflected in terms of reduced animal survival. The
GM-CFC numbers of both mouse and human
marrow decreased linearly with time as did the
repopulating capacity of the mouse marrow, all
three declining to -5% of the starting values by
72h. This suggests that GM-CFC may accurately
reflect repopulating ability and that the half-life of
marrow stored at 40C is - 24h.
Are cerebrospinal neurotransmitters related to
neurotoxicity in children receiving treatment for
acute lymphoblastic leukaemia?
C.R. Pinkerton', I. Smith2, R.J. Leeming3, G.
Curzon4 & G. Sarna4
'Department of Haematology & Oncology, Hospital
for Sick Children, Gt Ormond St., London, 2lnstitute
of Child Health, Guilford St., London, 3Dept.
Haematology, Birmingham General Hospital, 4Dept.
Neurochemistry, National Hosp., London
A variety of neurological syndromes have been
described in children with ALL and appear to be
related to chemotherapy and/or cranial irradiation.
It has been suggested that a possible contributory
factor is the inhibition of central neurotransmitter
synthesis by methotrexate due to its effects on
reductase enzyme systems (Abelson, 1978, Cancer
Treat. Rep., 62, 1999). To test this hypothesis the
concentrations of plasma biopterins, CSF
biopterins, homovanillic acid and 5 hydroxin-
dolacetic acid were estimated in 77 children with
ALL at various stages of treatment. Crithidia
bioassay was used for total biopterin measurement
and HPLC for HVA and 5 HIAA. There was a
significant elevation of plasma biopterins
(P<0.001) associated with chemotherapy which
persisted during maintenance treatment. This was
not, however, accompanied by a corresponding
decrease in HVA and 5HIAA. Moreover the trend
in treated cases was towards higher levels than
anticipated when corrected for the patient's age.
This has been described in the experimental animal
and it seems likely that MTX independent
pathways are utilized to maintain CSF neuro-
transmitter levels (Nichol, 1983, Proc. Natl Acad.
Sci., 80, 1546). There was no evidence in patients
studied sequentially that cranial irradiation altered
CSF biopterins, HVA or 5HIAA. It seems unlikely
therefore that the prophylactic administration of
neurotransmitters such as L-dopa, carbidopa or
5HT would protect against neurotoxicity, as has
been previously suggested (Cotton, 1978, Lancet, ii,
484).
Recombinant DNA human interferon alpha 2 (IFN)
in advanced breast cancer (abc)
N. Padmanabhan, F.R. Balkwill, J. Bodmer &
R.D. Rubens
ICRF Breast Cancer Unit, Guy's Hospital and ICRF
Laboratories, Lincoln's Inn Fields, London390 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Patients (pts) with evaluable progressive abc have
been treated in a randomised phase 2 trial to
receive IFN either 2megaUm-2day-1sc 3 x wk
(SI) or 50megaUm-2day-'iv in 50ml saline in
30min on Days 1 to 5 Q 3 wks (S2). 11 pts have
been accrued so far. Ten pts had prior chemo +
endocrine therapy (Rx) for abc, while 1 had
adjuvant chemoRx only. Responses were assessed
by UICC criteria. In 5 pts on S1, duration of Rx
varied from 5 to 21 wks. All pts progressed (pd) on
Rx. Six pts on S2 received 2 to 8 courses, 5 pd on
Rx & 1 had stable disease. Toxicity included fever,
chills, rigors, headache, myalgia, anorexia, nausea,
vomiting, tiredness, somnolence and weakness.
Bone marrow depression was seen in S1 and 2 but
dose modification was necessary only in S2. All pts
had transient elevation of liver enzymes.
Hyperglycemia (pt not known to have diabetes
prior to IFNRx), peripheral neuropathy (pt with
stable diabetes but without overt neuropathy prior
to IFNRx) and heart failure (pt without overt heart
disease but had received adriamycin in the past)
were noted in 3 different pts on S2. Pharmaco-
kinetic studies in pts on S2 showed a sharp rise in
serum IFN with a peak at 1 hr (1-4.5 KUml-1)
followed by a rapid decline (mean 1/2 life - 2.5 h).
Levels of peripheral blood lymphocyte's surface
HLA antigen were studied in 7 pts on Days 0, 1, 3
and 5, using monoclonal anti HLA-ABC and fl2
microglobulin antibodies. 2/3 pts on S2 showed a
marked rise in reactivity by Day 5 (1:800 to
1:6400). 1/4 pts on S1 showed a marginal increase
and 3 none. In conclusion, IFN in 2 different
regimens has not shown any evidence of activity
against abc after prior systemic Rx. (IFN was
supplied by Schering-Plough Corp.)
Mitoxantrone, a Phase II study in advanced breast
cancer
R.E. Coleman, M.N. Maisey, R.K. Knight & R.D.
Rubens
ICRF Breast Cancer Unit, Guy's Hospital, London
Mitoxantrone is an anthracenedione with some
structural similarities to Adriamycin. Thirty-four
patients with advanced breast cancer, who had not
received previous chemotherapy for advanced
disease were treated with Mitoxantrone 14mgm 2
i.v. every 21 days. Before commencing treatment,
and 3-monthly thereafter, measurements of
ventricular ejection fraction by gated blood pool
angiocardiography was performed at rest and in
response to stress (cold-pressor and isometric hand-
grip). Eleven of 33 evaluable patients (33%)
achieved a partial response. There were no
complete responders. The dose limiting toxicity was
marrow suppression. Dose reduction was necessary
in 106/220 courses (48%). Septicaemia occurred in
3 patients and was fatal in 2. Nausea and vomiting
was mild and transient (WHO grades 1 and 2) in
all but one patient. Two patients developed marked
allopecia. > 15% deterioration in ejection fraction
at rest and/or following stress was seen in 10
patients. Two patients developed reversible cardiac
failure. Mitoxantrone is an active, well tolerated
agent in the treatment of advanced breast cancer.
Cardiotoxicity does occur but the precise nature
and incidence requires further evaluation.
The treatment of advanced breast cancer with an
analogue of gonadtrophin releasing hormone
J.H. Waxman, M.L. Slevin, R.C. Coombes1, S.
Harland1, J.S. Malpas, P.M.F. Wrigley & T.A.
Lister
St Bartholomew's and Royal Marsden' Hospitals,
London
Twenty-five women with advanced breast cancer
(16 post- and 9 pre-menopausal) were treated with
D Ser (Bu')6 LHRH ethylamide (buserelin), a long
acting analogue of gonadotrophin releasing
hormone. Buserelin was given in divided dosages of
either 600 or 1000,ug daily intranasally for up to 7
months. Only one premenopausal and 4/8
postmenopausal women had received prior
hormonal therapy and responded. Oestrogen
receptors were present and measured in 4/6
premenopausal and none of 3 postmenopausal
women. Early minimal responses were observed in
I postmenopausal and 2 premenopausal patients.
Both premenopausal responses were in oestrogen
receptor positive patients but the oestrogen receptor
status of the postmenopausal women was unknown.
None of the responding patients had received
previous endocrine treatment. These results suggest
that buserelin may provide a further nontoxic
hormonal therapy for breast cancer in premeno-
pausal women, but its significance in the treatment
of postmenopausal patients has not been proven.
Distal transposition of the caecum in the rat does not
affect susceptibility to carcinogenesis
J.B. Rainey, M. Maeda & R.C.N. Williamson
University Department of Surgery, Bristol Royal
Infirmary, Bristol BS2 8HWABSTRACTS OF INVITED AND PROFFERED PAPERS 391
Like its human counterpart the appendix, the rat
caecum is relatively resistant to carcinogenesis,
possibly because of its luminal environment. We
therefore tested the effect of exposing caecal
mucosa to the distal faecal stream in male Sprague-
Dawley rats (n=50) given a selective intestinal
carcinogen. The colon was transected at the pelvic
brim and the caecum was inserted isoperistaltically
between colo-caecal and caeco-rectal anastomoses
(n=30). An ileo-colic anastomosis restored
intestinal continuity. Controls (n=20) had
transection and reanastomosis at equivalent points
of the bowel plus caecotomy and resuture.
Operations were performed 1 week after a 6-week
course of azoxymethane injections (total dose
90mgkg-1 s.c.).
Caecal crypt cell production rate, as determined
stathmokinetically at 28 weeks, was unaffected by
transposition. No tumours developed in either
transposed or orthotopic caecum apart from 3
suture-line tumours found at the caecotomy site in
controls. The colonic tumour yield in controls
(1.4+0.3 per rat:mean + s.e.) matched that after
transposition (1.5+0.2), but anastomotic tumours
were commoner after transposition (1.8 +0.3 vs.
0.8+0.3: P<0.05).
Transposed caecum remains relatively resistant to
carcinogenesis compared with distal colon. The
composition of faeces passing through the caecum
seems unimportant in maintaining this resistance,
which may be more readily attributable to local
epithelial mechanisms.
The effect of colitis upon the colonic carcinogen
dimethyl hydrazine in a rat model
P.G. Davey, E. McGuinness, S. Nicol & K.G.
Wormsley
Depts of Therapeutics and Pathology, Ninewells
Hospital and Medical School, Dundee DDI 9SY
The object of the experiment was to see whether
colitis increases the susceptibility of the rat to the
colonic carcinogen dimethyl hydrazine (DMH).
Colitis was induced in adult, male Sprague Dawley
rats by intrarectal injection of 10% acetic acid
(IRAA) through 3cm of PE240 polythene tubing
under ether anaesthesia. In preliminary experiments
we showed that a consistent degree of histological
inflammation was produced up to 12cm from the
anus. Three groups of 14 rats were studied: group
A received IRAA then 20 weekly s.c. injections of
10mg DMHkg-l in EDTA base; group B received
IRAA then 20 weekly s.c. injections of EDTA base
alone; group C received IR saline then 20 DMH
injections. Eight rats from group A were killed
because of severe colitis; all colons were dilated and
most had perforated. One rat in group B died with
a jejunal tumour at 17 weeks. The remaining rats
were sacrificed at 20 weeks. No metastatic lesions
were found in any rat and group B rats had no
colonic tumours. Adenocarcinomas were present in
the colons of all group A rats and 11/13 group C
rats; group A rats had significantly more tumours
per colon (Wilcoxon test, P<0.01); there were a
total of 25 tumours in the 6 group A rats and 19 in
the 13 group C rats. The stage of the tumours was
the same in both groups and most had penetrated
the submucosa, one tumour in each group
penetrated through the bowel wall. The tumours in
group A were significantly more distal (Wilcoxon
test, P<0.01) with most tumours occurring within
10cm from the anus whereas in group C tumours
were more common in the proximal and mid colon.
We conclude that DMH injections increase the
severity of colitis induced by acetic acid and that
the presence of colitis alters both the number and
distribution of DMH induced colon cancers in the
rat.
Intrarectal deoxycholate promotes experimental
colorectal carcinogenesis in the rat without affecting
the colonic bacterial population
J.B. Rainey, R. Veale & R.C.N. Williamson
University Depts Surgery & Microbiology, Bristol
Royal Infirmary, Bristol BS2 8HW
The case for bile acids as promoters of colorectal
carcinogenesis rests on human epidemiological data
and animal experiments. If direct exposure of
colorectal mucosa to bile acids altered the
composition of the faecal flora, itself implicated as
a modulator of carcinogenesis, animal experiments
might have limited relevance to human
carcinogenesis. The promotional effect of sodium
deoxycholate (SDC) was tested in male Sprague-
Dawley rats (n=70) which had received a 6-week
course of azoxymethane (total dose 90mgkg-1
s.c.). For the next 18 weeks 2 groups received thrice
weekly intrarectal instillations of 1 ml 0.12M SDC
(n=25) or 1 ml N saline (n= 25). Controls had no
instillations (n =20). At sacrifice (28 weeks),
colorectal tumour yield (controls 2.4+0.4 per rat:
mean + s.e.) was unaffected by intrarectal saline
(2.8 +0.5) but was almost trebled by intrarectal
SDC (6.4+0.5) P<0.01. SDC also increased mean
colonic crypt depth by 9% compared with the other
2 groups (P<0.001). Other rats (n=9) received
intrarectal SDC or saline or no instillations without392 ABSTRACTS OF INVITED AND PROFFERED PAPERS
carcinogen and were killed at 12 weeks. Total
colonic bacterial counts showed no consistent
differences between groups. Sodium deoxycholate
strongly promotes experimental colorectal carcino-
genesis. This effect is probably due to its tropic
action on the mucosa and is not related to any
concurrent change in bacterial flora.
Studies on the metabolic activation of chrysene
R.M. Hodgson, A. Weston & P.L. Grover
Chester Beatty Laboratories, Institute of Cancer
Research, Royal Cancer Hospital, Fulham Road,
London SW3 6JB
The polycyclic aromatic hydrocarbon chrysene is a
weakly active carcinogen on mouse skin, but the
dihydrodiol precursor of its "bay-region" diol-
epoxide is more carcinogenic than the parent
compound. Ether extracts of hamster embryo cell
cultures and mouse skin in vivo treated with
chrysene were examined for the presence of
dihydrodiol metabolites by t.1.c. and h.p.l.c. In
addition the chrysene-nucleoside adducts formed in
cultured hamster embryo cells, a rat liver
microsomal metabolizing system containing DNA
and mouse skin in vivo treated with 3H-labelled
chrysene were examined by Sephadex LH20 column
chromatography and by h.p.l.c. on Zorbax ODS.
All three possible dihydrodiols of chrysene were
detected in hamster embryo cells and mouse skin
treated with chrysene. A chrysene triol was also
found in mouse skin extracts. In hamster embryo
cells, the major DNA-adducts had chromatographic
properties identical to those of adducts formed
when the anti isomer of the "bay-region" diol-
epoxide of chrysene reacts with DNA. Both
guanosine- and adenosine-hydrocarbon adducts
were detected. NMR studies on the guanosine
adducts showed that the hydrocarbon is attached at
the exocyclic amino group of guanine. In the rat-
liver microsomal preparations and in mouse skin
treated with 3H-chrysene, adducts having
chromatographic properties identical to those
formed when anti-chrysene-1,2-diol 3,4-oxide reacts
with DNA were also detected. Additional adducts
were also present, however, which differed in their
chromatographic mobilities from synthetic DNA-
chrysene adducts formed from anti-chrysene-1,2-
diol 3,4-oxide. The results show that metabolic
activation of chrysene occurs via this "bay-region"
diol-epoxide but suggest that, in some biological
systems, this is not the sole route for the metabolic
activation of chrysene.
The nitrosation of drugs under chemical and
simulated gastric conditions
P.N. Gillatt1, R.J. Hart1, C.L. Walters1 & P.I.
Reed2
'Leatherhead Food Research Association,
Leatherhead, Surrey, 2Gastrointestinal Unit,
Wexham Park Hospital, Slough
Using the Nitrosation Assay Procedure (F.
Coulston, The potential carcinogenicity of nitro-
satable drugs (Norwood, 1980 Ablex Publ. Co.), 60
drugs have undergone nitrosation at pH 3.0 with a
molar ratio of nitrite:drug of 4:1. Volatile N-
nitrosamines formed have been determined
individually by gas chromatography with a Thermal
Energy Analyzer as selective detector. More
complex N-nitroso compounds have been
determined as a group using a chemiluminescence
analyzer as Walters et al. (1978) (Analyst, 103,
1127).
The great majority of nitrogenous drugs are
susceptible to the action of nitrous acid with the
production of volatile N-nitrosamines or more
complex N-nitroso derivatives or both. The extents
of formation have varied widely under standardised
chemical conditions, the nitrosation of secondary
amino drugs occurring generally more readily than
secondary amides, tertiary amines, hydrazides and
carbamates with the exception of aminopyrine and
minocycline, both of which are tertiary amines
giving rise rise to high yields of N-nitrosodimethyl-
amine (NDMA).
Nitrosations are being extended to simulated
gastric conditions so as to ascertain the likely
contact with a N-nitroso compound(s), the vast
majority of which are carcinogenic in experimental
animals, of a person treated with the normal daily
dose of a series of drugs. So far, the yields of N-
nitroso compounds as a group have ranged from
102-104 times less than those obtained under the
conditions of the NAP test.
An experimental animal model for human invasive
bladder cancer
R.M. Hicks, K. Nandra, J. Turton, N. Tomlinson,
J. Gwynne, E. Chrysostomou & M. Pedrick
School of Pathology, Middlesex Hospital Medical
School, London WIP 7LD
Human papillary cancer usually presents as a
superficial, well-differentiated papillary lesion,ABSTRACTS OF INVITED AND PROFFERED PAPERS 393
controllable by local resection for many years, but
once carcinoma in situ(cis) and/or flat invasive
transitional cell carcinoma (tcc) develop, bladder
cancer is an aggressive neoplasm, difficult to
control and often fatal. Several rodent models are
available for the superficial papillary disease but
none give reliably high incidences of cis or invasive
tcc. We report here the availability of a rodent
model for cis and tcc, developed from that
described by Becci et al. (Cancer Res., 1981, 41,
927). The female B6D2F1 mouse, dosed intragastri-
cally with N-butyl-N-(4-hydroxybutyl) nitrosamine
(BBN), develops cis which rapidly progresses to
invasive tcc, which is histologically very comparable
to the human disease. Tumour incidence is directly
related, and the latent period inversely related, to
the dose of BBN. The time-course of cancer
development was monitored by sampling 5-8 mice
per group at regular intervals. By 50 weeks after
30mg BBN given weekly as 10 equal aliquots the
cumulative incidence was 28%; after 15mg BBN it
was 7% but after 10mg there were no carcinomas.
The lesions progressed from cis to flat invasive P1
and P2 tcc, and then to poorly-differentiated P3
lesions in which cancer cells invaded the peritoneal
surface. In some areas squamous metaplasia
developed and in others the growth pattern was
adenomatous. This model provides a valuable new
tool with which to study the development,
treatment and modulation of invasive bladder
cancer.
Comparison of polyclonal and monoclonal anti-EMA
antibodies
E. Heyderman', G. Powell', T.C. Richardson1,
D.V. Chapman', J.L. Cordell2 & D.Y. Mason2
'Dept Histopathology, St Thomas Hospital, London,
SE] 7EH, 2Dept Haematology, John Radcliffe
Hospital, Oxford
The ubiquitous nature of an antigen, or group of
antigens, termed Epethelial Membrane Antigen
(EMA), was first reported to this association in
1978 (Heyderman et al., Br. J. Cancer, 1978, 39,
473). It was localised by the immunoperoxidase
technique in a variety of tissues using polyclonal
antibodies raised against human milk fat globule
membranes. These antibodies have since been used
extensively for the diagnosis and differential
diagnosis of a variety of malignant tumours. To
increase specificity, rabbit antibodies have been
affinity-purified on an agarose column (AffiGel 10,
BioRad, Herts) to which a preparation of milk fat
globule membranes had been bound. Yields from
this purification step were small, and the antibodies
could not readily be made available to other
workers. Monoclonal antibodies can be produced in
large quantities, so we have compared the results of
staining 25 different neoplastic and non-neoplastic
tissues with a polyclonal unpurified rabbit anti-
EMA (Dr Ormerod, ICR, Sutton), our affinity-
purified antibody, and two monoclonal hybridoma
antibodies, MFGM2 (Seward Laboratory,
London), and our own monoclonal, E29/68. The
tumours included carcinomas of the breast, colon,
lung, kidney, ovary, and skin, and a malignant
teratoma of the testis with epithelial differentiation.
The non-neoplastic specimens consisted of pituitary,
pancreas, skin, placenta, lactating breast, tonsil and
hyperplastic prostate. While the distribution of
staining with the four antibodies was similar, the
hydridoma antibodies produced a less extensive
staining pattern, and retained the membrane
staining of some plasma cells. A combination of the
two monoclonals was also assessed.
The heterogeneity of CEA expression in gastric
carcinoma
F. Macdonald, M.S. Hockey, H. Stokes & J.W.L.
Fielding
Dept. Surgery, Queen Elizabeth Hospital,
Birmingham
Monoclonal antibodies to different epitopes of
CEA were used in an indirect immunoperoxidase
test to study CEA expression in primary gastric
tumours and metastases and to evaluate CEA as a
potential target for therapeutic or diagnostic agents.
Ninety-three per cent of 216 primaries and 82% of
148 autologous metastases examined with one
antibody (Ll 1-285-14) specific for CEA were
positive. There was good correlation between CEA
status of the primaries and metastases. However, in
patients where two or more nodes were examined,
20% had both positive and negative nodes.
Individual primaries and metastases were also
heterogenous for CEA expression. Serial sections of
14 primaries and 14 metastases were therefore
examined with 2 further monoclonal antibodies to
different epitopes of CEA and 2 polyclonal anti-
CEA antibodies to determine whether this
heterogeneity reflected differences in CEA
expression in different populations of cells or the
specificity of the monoclonal antibody. All tumours
negative with one antibody were negative with all
and vice versa. All antibodies reacted with the same
tumour cells. While CEA remains the most
potentially useful antigen in gastric carcinoma, this394 ABSTRACTS OF INVITED AND PROFFERED PAPERS
study has demonstrated some possible limiting
factors in both follow-up radioimmunolocalisation
and drug targetting, even using a monoclonal
"cocktail".
Studies of WGA-binding proteins of metastatic
tumour cells, macrophages and other cell types
W.-S. Chan, A. Jackson & G.A. Turner
University Dept. Clinical Biochemistry & Metabolic
Medicine, Royal Victoria Infirmary, Newcastle upon
Tyne NE] 4LP
We have demonstrated (Chan et al., 1982, Br. J.
Cancer, 46, 474) higher Wheat Germ Agglutinin
(WGA) binding to glycoproteins extracted from a
s.c. transplanted hamster lymphosarcoma (1°) as
compared to the binding to proteins from its liver
metastases (20). This difference has been further
investigated by subjecting tumour cell suspensions
to various cell separation techniques and the
protein extracts from these subpopulations analysed
by using electrophoresis and 1251-WGA labelling.
For comparison, extracts of potential tumour host-
cell infiltrators, in particular macrophages, have
been examined. Macrophage-rich populations
prepared from 1° tumours by using density
gradients showed increased expression of WGA-
binding proteins. Only certain types of non-tumour
macrophages expressed WGA-binding patterns that
were similar to the 10 tumour pattern. However,
macrophage-depleted tumour cell populations
isolated by density gradients or carbonyl iron
treatment or a cell adhesion technique still showed
substantial WGA-binding. After further purification
of these cell suspensions using unit gravity
separation, the WGA-binding pattern was very
similar in all fractions irrespective of its
composition. Some of the high content of WGA-
binding proteins in this 10 tumour, therefore, can
be accounted for by the presence of infiltrating
macrophages (-9% total cell no.), but tumour cells
also seem to express very similar surface glyco-
proteins. Metastatic cells express these proteins very
weakly; a reason for this difference awaits further
investigation.
Studies on serum galactosyl transferase in cancer
patients
P.A. Light, K. Howe, A.W. Preece, V.L. Barley &
K.A. Walter
Research Unit, Radiotherapy and Oncology Centre,
Bristol BS2 8ED
The activity of the enzyme galactosyl transferase
(GT) has been reported to be elevated in the serum
of patients with certain types of cancer. We have
measured GT activity in serum of 305 patients with
cancer (85% ca breast) and in 92 other subjects
without malignant disease. The mean values of
these groups were 31.0+27.3 and 21.5+7.2 units
respectively. In the cancer group, of the 167
patients who had GT values above that of the
control group, 92% had clinically active disease.
However, in the remainder with low or normal
values there were at least 30% with active disease.
Serial samples taken during several months from
ten patients showed close correlation with disease
activity in 6 patients, but apparently little
correlation in the remainder. Analogous studies
using the L2C tumour in guinea pigs showed that
serum GT activity correlated precisely with tumour
burden. It has been suggested that the isoenzyme
GT2 may be a more specific marker of malignant
growth. However, we have not been able to
confirm this observation. If the technique for
measuring GT activity could be simplified then the
assay might be a worthwhile additional test in
monitoring progress of some patients. However, the
present combination of a very time-consuming
assay and the uncertainty in recognizing false
negative results restricts its usefulness until
improvements in techniques can be introduced.
Viability studies on exfoliated colorectal cancer cells
recovered from sites of intestinal transection and
isolated on Nycodenz columns
H.C. Umpleby, B. Fermor, M.O. Symes & R.C.N.
Williamson
University Department of Surgery, Royal Infirmary,
Bristol
Exfoliated colorectal cancer cells are reported to be
non viable and therefore an unlikely cause of
suture-line recurrence recurrence following resection
of large bowel tumours (Rosenberg et al. (1978), Br.
J. Surg., 65, 188). The presence and viability of
exfoliated colorectal cancer cells at the proximal
and distal sites of transection were investigated in
30 freshly-resected tumour specimens. Clamps were
applied 3 cm from the transected bowel ends.
Irrigation with tissue culture medium was
performed on all proximal ends and on 25 distal
ends. There were 5 cases of abdomino-perinealABSTRACTS OF INVITED AND PROFFERED PAPERS
Trypan blue exclusion
Cases No. viable tumour Distance (cm)
viable tumour cellsx 105 Median Fluorescence from tumour
cells (median+range) % viability (no. cases) (median+range)
Proximal 17 0.55(0.25-12.5) 92.5 15 10.8(4-35)
Distal 21 1.92(0.25-22) 79.3 21 7.5(3-20)
resection and 9 of right hemicolectomy. Tumour
cells were isolated on Nycodenz density centri-
fugation columns (Umpleby et al. (1983), Br. J.
Cancer, 48, 127), and viability was determined by
exclusion of the supravital stain trypan blue, and
by hydrolysis of fluorescein diacetate to produce
detectable fluorescence.
In 5 cases viable tumour cells were isolated from
the ileum. Independent cytological examination
confirmed tumour cells in all cases demonstrating
viable cells. Large numbers of viable cancer cells
are shed into the intestinal lumen and could
therefore implant on the freshly created
anastomosis.
between the nucleated cell count and the period of
thrombocytopenia (P<0.01). We conclude
therefore, that autologous marrow transplantation
accelerates haemopoietic recovery in children with
solid tumours treated with high dose melphalan.
Depressed natural killer activity in patients with
malignant lymphoma
F. Healy, R.C. Rees & R.W. Hancock
Depts Virology and Medicine, University ofSheffield
Autologous bone marrow transplantation contributes
to haemopoietic recovery in children with solid
tumours treated with high dose melphalan
J.E. Kingston', J. Pritchard2, J.S. Malpas' & T.J.
McElwain3
'St Bartholomew's, 2Great Ormond Street & 3Royal
Marsden Hospitals, London
During a 5 year period 65 children with advanced
stage malignant solid tumours have been treated
with high dose melphalan (100-220mgm-2)
combined with non cryopreserved autologous
marrow transplantation. Forty-five of the children
were given a "priming" dose of cyclophosphamide
(300mgm-2) one week before treatment with
melphalan. All children developed profound
neutropenia and thrombocytopenia following high
dose melphalan; the nadir of the neutrophil and
platelet counts occurring at median intervals of 7
and 10 days respectively. The duration of
neutropenia (median 11 days) and the duration of
thrombocytopenia (median 18 days) did not appear
to be affected by the dose of melphalan, suggesting
that the initial recovery of the peripheral blood
count results from the engrafted autologous
marrow. There was a highly significant negative
correlation between the nucleated cell count of the
reinfused marrow and the period of neutropenia
(P<0.001) and a significant negative correlation
The Natural Killer (NK) activity of peripheral
blood lymphocytes (PBL) and whole blood from
patients with malignant lymphoma, prior to
treatment, was found to be significantly depressed
when compared with controls. This is consistent
with an intrinsic defect in the cell-mediated immune
system, which is commonly found in these patients.
A positive correlation was observed between the
level of natural killing of PBL from HD patients
and the age of the patients, although this was not
seen with non-HD patients or with controls.
However, among non-HD patients a positive
correlation was observed between NK activity and
the stage of disease, i.e., stage III and IV patients
had significantly higher levels of NK activity than
stage I and II patients. There was no correlation
between the level of NK activity of lymphoma
patients and either the histological type of disease
or the sex of patients. NK activity of PBL from the
majority of patients tested (12/18) could be boosted
by pre-incubation with interferon and similarly the
activity of whole blood samples from 7/10 patients
was boosted by interferon. Using the monoclonal
antibody Leu-7 as an NK marker, it was shown
that the number of cells expressing this antigen in
the peripheral blood of non-Hodgkin's patients was
within the normal range, although expression of
Leu-7 did not correlate with NK activity.
Preliminary studies suggest that the number of
Leu-7+ cells in HD patients is also in the normal
range.
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Depressed natural killer cell activity in blood
draining digestive tract tumours in man
R.C. Rees, K. Rogers & C.D.M. Griffith
Depts Virology and Surgery, The University of
Sheffield Medical School
The functional status of natural killer (NK) cell
activity was assessed in patients undergoing surgery
for digestive tract carcinoma or benign conditions.
The level of natural killing was assessed in
peripheral venous blood, the aortic blood supply to
the tumour, and the tumour draining venous blood.
NK cell activity of peripheral venous blood taken
from cancer patients was significantly depressed
compared with benign controls (pre-operative blood
samples). In addition, assessment of the activity
present in the blood draining the primary tumour
site was shown to be significantly less than the
activity present in the aortic blood suggesting that
lymphocyte function is influenced as a result of
passage through the tumour site. Plasma samples
from either the tumour venous blood supply, or the
peripheral venous supply were assessed for their
effect on natural killing, mediated by peripheral
blood lymphocytes from normal individuals. Blood
plasma recovered from tumour draining blood
caused significant (P=0.01) inhibition of NK cell
killing of K562 targets in the majority of tests
performed, whereas the corresponding peripheral
venous blood from the same patients was only
inhibitory in 25 per cent of cases. There was no
significant change in the total number of blood
lymphocytes before and after passage through the
tumour (aortic versus tumour-venous blood
lymphocytes) or in total white blood cell counts.
Fluorescent staining with monoclonal antibody
against lymphocyte surface markers also failed to
reveal significant alterations in the level of T-
lymphocytes and Leu-7 (NK marker) positive
lymphocytes across the tumour. This study infers a
role for soluble factors released from the primary
tumour mass, in mediating depression of NK cell
function.
Characterisation of mononuclear cells of infiltrates in
human colorectal carcinomas using monoclonal
antibodies
H.C. Umpleby, D. Heinemann, M.O. Symes &
R.C.N. Williamson
Dept. ofSurgery, University ofBristol, Bristol
Serial frozen sections were prepared from 11
colorectal carcinomas and from adjacent normal
bowel in 7 of these cases. The mononuclear cell
infiltrates were stained by indirect immunoperoxi-
dase using a panel of mouse monoclonal antibodies
to human leucocyte antigens. The degree of
infiltration was graded 5 (heavy), 4 (moderate). 3
(few), 2 (occasional) and 1 (nil). Assessment was
performed by two independent observers. All
sections of carcinoma save one showed a heavy or
moderate infiltrate with leucocytes (anti HLe-1)
among which T cells (UCHT-1) were predominant.
There was an excess (graded 3-4) of
suppressor/cytotoxic T cells (UCHT 4) over
helper/inducer T cells (OKT 4) (graded 1-2) in 8
tumours. The T cells were not all activated as
indicated by the reduced number (graded 2-3)
staining with HLA-DR antibody (OK lal). No NK
cells were found in 2 tumours tested (HNK-1). The
findings for adjacent normal bowel were similar
except that suppressor/cytoxic T cells did not
predominate over helper/inducer T cells. The excess
of cytotoxic T cells in tumour tissue is consistent
with the cytotoxicity of tumour infiltrating
lymphocytes for autoplastic tumour cells
(Hutchison et al., (1981), Br. J. Cancer, 44, 396)
and the positive relationship between lymphoid
infiltration in tumours and a favourable prognosis
(Underwood, (1974), Br. J. Cancer, 30, 538;
Hutchinson et al., (1983), J. Exp. Clin. Cancer Res.,
2, 161).
Transplantability of tumour cell clones before and
after passage in immunodeficient hosts
M.F.A. Woodruff", B.A. Hodson2 & J.A. Ansell'
1MRC Clinical and Population Cytogenetics Unit,
Edinburgh, and 2Department of Zoology, University
ofEdinburgh
Cloned cell lines from strongly immunogenic
methylcholanthrene-induced murine fibrosarcomas
often fail to grow when transplanted s.c. directly
(106-2 x 106 viable cells) to normal syngeneic hosts.
Uncloned populations from the primary tumour
transplant readily but long-cultured uncloned lines
may fail to do so. Cloned and uncloned cell lines
grow readily in thymectomized, heavily irradiated
(730 rad) mice protected with cytosine arabinoside,
sublethally irradiated (495 rad) and nude mice, and
after such passage usually grow in normal mice.
Studies with one particular unpassaged clone have
shown that it fails to grow in normal mice over a
wide dose range (103-107 cells), when mixed with
untreated or irradiated peritoneal exudate cells or
cells of another clone, or when a passaged clone isABSTRACTS OF INVITED AND PROFFERED PAPERS 397
transplanted elsewhere in the same host, but does
grow in mice irradiated up to 24 (exceptionally 48)
h after tumour inoculation. We postulate that
cloned lines are vulnerable to the combined effect
of mechanisms mediated by T cells and NK or
related cells but escape if either component is
missing. During passage in hosts deficient in T but
not NK cells, a tumour cell population emerges
which is NK cell resistant and can therefore grow
in normal mice. To test this hypothesis we are
studying the sensitivity of passaged and unpassaged
clones to killing by isogenic spleen cells in vitro, and
the transplantability of clones passaged in hosts
deficient in both T and NK cells.
Migration of human T and B lymphocytes in three-
dimensional collagen matrices
W. Shiu & S. Schor
CRC Department of Medical Oncology, Christie
Hospital & Holt Radium Institute, Manchester
We have previously presented quantitative data
regarding the migration of unfractionated human
peripheral blood lymphocytes into three-
dimensional collagen matrices (Schor et al., J. Cell
Biol., (1983), 96, 1089). Using this experimental
system, we now present data regarding the
comparative migratory behaviour of fractionated T
and B lymphocyte subsets. Enriched populations of
T and B lymphocytes were prepared by standard
rosetting techniques using sheep red blood cells.
The cellular constituents of the enriched
populations were estimated by immunofluorescent
microscopy using BAI (Hybritech) and UCHTI
(supplied by Dr P. Beverley) monoclonal anti-
bodies; the enriched lymphocyte populations
contained 90% T cells and 70% B cells respectively.
When plated on the surface of the collagen gel
matrix, T and B cells were observed to enter the
collagen matrix at the same rate. Once within the
collagen matrix, however, T cells migrated signi-
ficantly faster than B cells. As previously shown for
the unfractionated lymphocytes, the migration of
both T and B cells was found to occur by a random
walk mechanism.